# Chicago Alternative Prevention Study for BReast CAncer in Diverse Populations of High-Risk Women (CAPSBRACA)

> **NIH NIH R01** · UNIVERSITY OF CHICAGO · 2024 · $1,167,195

## Abstract

PROJECT SUMMARY
Risk-stratified breast cancer screening strategies are a paradigm shift from the one-size-fits-all screening
approach. Previous age-based screening strategies proved to be disadvantageous to specific high-risk
populations, particularly BRCA1 and BRCA2 mutation carriers and individuals of African ancestry at high risk for
aggressive young onset interval breast cancers. There is an unmet clinical need to identify women who are at
high risk of aggressive interval breast cancer that would have a poorer outcome without intensive surveillance.
Since joining the Women informed to screen based on measures of risk (Wisdom) Study (clinicaltrials.gov:
NCT02620852) in 2020, the UChicago site has enrolled 1691 participants; 64.7% White, 23.5% Black and 6.8%
Hispanic because of our location on the south side of Chicago and highly effective recruitment efforts in
communities of Color. A growing number of studies have demonstrated the diagnostic equivalency of
abbreviated MRI to the full MRI protocol. We launched the Chicago Alternative Prevention Study
for BReast CAncer (CAPSBRACA; clinicaltrials.gov:NCT00989638) as a P20 Breast Cancer Disparities SPORE
population science project to test the hypothesis that state-of-the-art genomic testing to identify women at
increased risk, combined with state-of-the-art MRI techniques, could effectively detect and downstage
aggressive interval breast cancers, and provide a personalized approach for management of high-risk women
in diverse populations. At our single Institution, 130 genomically defined high-risk participants (mean age 42
SD+12) have been enrolled including 44 BRCA1, 42 BRCA2, 7 PALB2 and 25 with PRS >30%, suggesting
common genetic variants can identify extremely high-risk women in practice. We have demonstrated the
feasibility of our approach and the proposed study will test that it is clinically effective, adaptable, and can scale
to optimize a comprehensive surveillance program for high-risk women using the Wisdom platform. Our overall
objective is to expand to three additional sites in California to broaden the diversity of study sites and participants.
The specific aims are to: 1) Implement biannual abbreviated MRI that includes ultrafast- DCE-MRI, with
multicenter standardization; refine and expand our high-risk biannual abbreviated protocol to be fast, while both
clinically accurate and generalizable across imaging facilities; 2) perform correlative science and quantitative
analysis of MRI images and build an analysis package that can be disseminated to other centers; and 3) Develop
and evaluate self-supervised deep learning (SSL) methods using UF DCE-MRI to enable fast and accurate
computational biomarkers of breast cancer risk. CAPSBRACA translates innovative genomics and imaging
research from the laboratory into meaningful clinical interventions and has the potential to address an unmet
clinical need for early and accurate detection of aggressive young-onset breast cancers in mutation...

## Key facts

- **NIH application ID:** 10906175
- **Project number:** 5R01CA276652-02
- **Recipient organization:** UNIVERSITY OF CHICAGO
- **Principal Investigator:** Hiroyuki Abe
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $1,167,195
- **Award type:** 5
- **Project period:** 2023-08-11 → 2028-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10906175

## Citation

> US National Institutes of Health, RePORTER application 10906175, Chicago Alternative Prevention Study for BReast CAncer in Diverse Populations of High-Risk Women (CAPSBRACA) (5R01CA276652-02). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10906175. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*